- SCHOTT Pharma begins construction on a new production facility for ready-to-use cartridges in Hungary.
- The company’s investment of more than EUR 100 million is part of its expansion strategy to fulfil the growing market demand for high-value solutions.
- The new production facility will be developed at SCHOTT Pharma’s current plant in Lukácsháza, creating more than 100 new employments.
- SCHOTT Pharma’s Lukácsháza plant is already a major supplier of drug containment and delivery systems to the global industry. In June 2024, the business launched a cutting-edge facility at the location for high-quality prefillable glass syringes, which are commonly used to store GLP-1 treatments, essential vaccinations, and biologics. Since then, with 120 new staff on board, manufacturing has begun, and further production capacity has been added.
- With RTU cartridges, the company is hoping to expand its manufacturing capacity for high-value products at the site, which has enough room to fulfil the company’s expansion goal. “We would like to thank the Ministry of Foreign Affairs and Trade for its support of these two expansion projects. “Lukácsháza is not only an important location for ensuring supply security for regional customers, but it also contributes significantly to SCHOTT Pharma’s global growth strategy,” explains Eva Szabó, Site Manager Lukácsháza.
The state-of-the-art RTU cartridge production plant will be outfitted with the newest cutting-edge technology thanks to its solid foundation and sophisticated capabilities. In order to drastically lessen its impact on the environment, this facility will have a cutting-edge steam sterilisation method and an advanced washing line. There will be very little manual intervention because the production process will be fully automated and seamlessly connected. As a consequence, the sector will produce superior sterile products. Lukácsháza will proudly become SCHOTT Pharma’s second sterile RTU cartridge production facility, after St. Gallen, Switzerland.
